Reference health
Moving immune therapy forward targeting tme
39/39 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
1 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 39 checked references that resolve
resolves10.1155/2019/4508794
Current Challenges in Cancer Immunotherapy: Multimodal Approaches to Improve Efficacy and Patient Response Rates
resolves10.1126/scitranslmed.3002842
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
resolves10.1152/physrev.00018.2019
Immunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy
resolves10.3389/fimmu.2018.00353
Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy
resolves10.1200/JCO.2019.37.15_suppl.e14228
A novel dual inhibitor of IDO and TDO, CMG017, potently suppresses the kynurenine pathway and overcomes resistance to immune checkpoint inhibitors.
resolves10.3390/genes10040264
The Complex Interplay between Metabolic Reprogramming and Epigenetic Alterations in Renal Cell Carcinoma
resolves10.1073/pnas.1902145116
Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy
resolves10.1126/scitranslmed.aak9670
Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade
resolves10.1016/j.cmet.2019.02.016
Membrane Cholesterol Efflux Drives Tumor-Associated Macrophage Reprogramming and Tumor Progression
resolves10.1038/s41571-019-0203-7
Navigating metabolic pathways to enhance antitumour immunity and immunotherapy
resolves10.3389/fimmu.2017.01300
Pyruvate Kinase M2 Is Required for the Expression of the Immune Checkpoint PD-L1 in Immune Cells and Tumors
resolves10.1038/s41388-019-0735-4
Targeting LIN28B reprograms tumor glucose metabolism and acidic microenvironment to suppress cancer stemness and metastasis
resolves10.1038/s41586-019-0904-1
Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity
resolves10.1038/s41590-018-0292-y
Metabolic rewiring of macrophages by CpG potentiates clearance of cancer cells and overcomes tumor-expressed CD47−mediated ‘don’t-eat-me’ signal
resolves10.1038/s41586-019-1170-y
CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy
resolves10.1158/0008-5472.CAN-15-1743
Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy
resolves10.1016/j.semcancer.2017.03.001
Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation
resolves10.3389/fimmu.2019.00925
Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function
resolves10.1155/2019/2084195
Targeting L-Lactate Metabolism to Overcome Resistance to Immune Therapy of Melanoma and Other Tumor Entities
resolves10.1126/science.aan4236
Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
resolves10.1016/j.ccell.2018.03.015
The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy
resolves10.1038/s41467-020-16079-x
Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer
resolves10.1038/s41467-019-10427-2
Identification of metabolic vulnerabilities of receptor tyrosine kinases-driven cancer
resolves10.1016/j.canlet.2017.07.027
Blockade of Stearoyl-CoA-desaturase 1 activity reverts resistance to cisplatin in lung cancer stem cells
resolves10.1186/s13045-019-0770-1
Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy
resolves10.1016/S1470-2045(19)30274-8
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
resolves10.7554/eLife.52176
Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies
The 1 reference without a DOI — listed, not checked
no DOI — not checkedImmune to Cancer: The CRI Blog
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1152/physrev.00008.2020"><img src="https://citestamp.com/citestamped/10.1152/physrev.00008.2020/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1152/physrev.00008.2020)